

**From:** [REDACTED]  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** Celestone Chronodose ADR report due to possible product contamination [SEC=UNCLASSIFIED]  
**Date:** Monday, 11 July 2016 5:50:47 PM

---

Dear [REDACTED]

I refer to the adverse event report of fungal joint infection following Celestone Chronodose intra-articular injection (ADR 386482, your reference AUS/16/0843) submitted to the TGA on the 19<sup>th</sup> of April 2016. Please be aware that the TGA has recently received a second report of fungal joint infection with *S. prolificans* after intra-articular injection with Celestone Chronodose in a different patient.

We are investigating further and will be in touch if we require any information.

Kind regards,

[REDACTED]  
Medical Officer  
Adverse Event Monitoring and Vaccine Safety  
Pharmacovigilance and Special Access Branch

Phone: [REDACTED]

Email: [REDACTED]

**Therapeutic Goods Administration**

Department of Health  
PO Box 100  
Woden ACT 2606 Australia  
[www.tga.gov.au](http://www.tga.gov.au)